Cynata Therapeutics Limited Fundamental Analysis
Cynata Therapeutics Limited (CYP.AX) shows moderate financial fundamentals with a PE ratio of -7.37, profit margin of 98.88%, and ROE of -1.79%. The company generates $-0.0B in annual revenue with weak year-over-year growth of -18.59%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -153.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CYP.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakCYP.AX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCYP.AX trades at attractive valuation levels.
Growth Score
ModerateCYP.AX shows steady but slowing expansion.
Financial Health Score
ExcellentCYP.AX maintains a strong and stable balance sheet.
Profitability Score
WeakCYP.AX struggles to sustain strong margins.
Key Financial Metrics
Is CYP.AX Expensive or Cheap?
P/E Ratio
CYP.AX trades at -7.37 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CYP.AX's PEG of -0.27 indicates potential undervaluation.
Price to Book
The market values Cynata Therapeutics Limited at 18.27 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -6.63 times EBITDA. This is generally considered low.
How Well Does CYP.AX Make Money?
Net Profit Margin
For every $100 in sales, Cynata Therapeutics Limited keeps $98.88 as profit after all expenses.
Operating Margin
Core operations generate 169.74 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-1.79 in profit for every $100 of shareholder equity.
ROA
Cynata Therapeutics Limited generates $-1.86 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cynata Therapeutics Limited generates strong operating cash flow of $-9.09M, reflecting robust business health.
Free Cash Flow
Cynata Therapeutics Limited generates strong free cash flow of $-9.09M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $-0.04 in free cash annually.
FCF Yield
CYP.AX converts -13.52% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-7.37
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.27
vs 25 benchmark
P/B Ratio
Price to book value ratio
18.27
vs 25 benchmark
P/S Ratio
Price to sales ratio
-759.14
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.49
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-1.79
vs 25 benchmark
ROA
Return on assets percentage
-1.86
vs 25 benchmark
ROCE
Return on capital employed
-4.26
vs 25 benchmark
How CYP.AX Stacks Against Its Sector Peers
| Metric | CYP.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -7.37 | 29.34 | Better (Cheaper) |
| ROE | -179.37% | 688.00% | Weak |
| Net Margin | 9887.90% | -52372.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.49 | Strong (Low Leverage) |
| Current Ratio | 2.49 | 4.37 | Strong Liquidity |
| ROA | -186.25% | -20476.00% (disorted) | Weak |
CYP.AX outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cynata Therapeutics Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-86.25%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-31.98%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-31.65%
Industry Style: Defensive, Growth, Innovation
Declining